Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution
- PMID: 17879372
- DOI: 10.1002/cncr.22967
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution
Similar articles
-
"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.Arch Intern Med. 2006 Jul 24;166(14):1446-8. doi: 10.1001/archinte.166.14.1446. Arch Intern Med. 2006. PMID: 16864753 Review. No abstract available.
-
[Contribution of Japan to develop new anticancer agents].Gan To Kagaku Ryoho. 1996 Jan;23(2):242-6. Gan To Kagaku Ryoho. 1996. PMID: 8611054 Review. Japanese.
-
Phase 0 clinical trials in oncology: a paradigm shift for early drug development?Cancer Chemother Pharmacol. 2009 Mar;63(4):703-9. doi: 10.1007/s00280-008-0789-4. Epub 2008 Jul 10. Cancer Chemother Pharmacol. 2009. PMID: 18615251 Review.
-
Shortening the timeline of pediatric phase I trials: the rolling six design.J Clin Oncol. 2008 Jan 10;26(2):190-5. doi: 10.1200/JCO.2007.12.7712. J Clin Oncol. 2008. PMID: 18182661
-
New adaptive method for phase I trials in oncology.Clin Pharmacol Ther. 2008 Jun;83(6):873-81. doi: 10.1038/sj.clpt.6100383. Epub 2007 Oct 24. Clin Pharmacol Ther. 2008. PMID: 17957185
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources